首页 正文

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers

{{output}}
Background: Remarkable advancements in the therapeutic armamentarium for medullary thyroid cancer (MTC) have been observed in the last 10 years. The current understanding of driver mutations, such as RET and RAS, has enabled the ... ...